Merck & Co., Inc. vs Spotify Technology — how do they compare? Merck & Co., Inc. trades at $132.94 (market cap $321.77B), while Spotify Technology trades at $489.8 (market cap $103.00B). The key difference: Merck & Co., Inc. is far larger — about 3.1× Spotify Technology's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| MRK | SPOT | |
|---|---|---|
Market Cap | $321.77B | $103.00B |
Sector | Health | Media |
52-Week High | $131.84 | $738.53 |
52-Week Low | $77.60 | $412.75 |
Enterprise Value | $368.53B | $92.70B |
Dividend Yield | 2.61% | — |
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Spotify (SPOT) trades at $489.65, down 4.33% in the last session, amid mixed technical signals and strong fundamentals. The stock shows a bullish moving average trend but neutral oscillators, with key support at $487. Financially, revenue grew to $17.19B in 2025 with a net income margin of 12.87%, while recent news highlights initiatives like AI artist labeling to enhance transparency.
Outlook remains positive with a consensus price target of $598.20, implying 22% upside, driven by subscriber growth and margin expansion. Risks include competitive pressures and cost management, but analyst sentiment is bullish with 62% buy ratings, supporting long-term value for investors.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →